Results from the 377-subject trial show a clinically meaningful benefit to subjects in the reduction of lactose intolerance symptoms across a variety of outcome measures. The majority of
The collaboration combines Warp Drive’s Small Molecule-Assisted Receptor Targeting (SMART™) platform with GSK’s expertise in Encoded Library Technology (ELT) to discover drugs that address high-value intractable targets. “This
Antimicrobial resistance is one of the greatest threats to global human and animal health – the O’Neill Report published last year stated that, unless we take urgent action, it will
This follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data Monitoring Committee ('DMC') and its support of Summit's plans
Ignyta had previously disclosed it was in discussions with Lilly regarding the optimal path forward for taladegib in the context of its pipeline priorities, which are focused substantially
PureTech Health will develop these new product candidates in an operating subsidiary, resTORbio, with an initial focus on diseases related to immunosenescence, an age-related decline in immune function.
Amgevita is authorized for the treatment of certain inflammatory diseases in adults, including moderate-to-severe rheumatoid arthritis; psoriatic arthritis; severe active ankylosing spondylitis (AS); severe axial spondyloarthritis without radiographic
Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made
Akashi plans to initiate a new study, HALO-DMD-04. “We are pleased to learn that the FDA is allowing Akashi to resume the clinical development of HT-100,” said Pat
The initiative will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.